Rachel Delinger

BACKGROUND: Waldenström macroglobulinemia (WM) is a rare, incurable non-Hodgkin Lymphoma. There is limited real-world evidence on WM treatment among US Veterans.

OBJECTIVE: This retrospective observational study aims to evaluate the real-world treatment patterns and associated outcomes among patients with WM in the Veteran Health Administration (VHA) population.

METHODS: Adults who had ≥2 visits with WM diagnosis codes and ≥1 WM treatment were identified in VHA database (2014-2018). Index date was defined as the first date of WM treatment. Patients included were newly diagnosed, initiating treatment, and enrolled continuously for 6 months prior to and ≥60 days following index date. Treatment regimens were categorized as: rituximab monotherapy, ibrutinib-based, chemotherapybased, proteasome inhibitor-based and other regimens. Healthcare resource utilization examined included hospitalization and length-of-stay (LOS). Total costs were calculated as sum of inpatient, outpatient and pharmacy costs per-patient-per-month (PPPM).

RESULTS: Prevalence and incidence of WM among Veterans ranged from 11.4-12.8 cases, and 0.4-1.6 cases per 100,000 persons, respectively. A total of 255 patients (median age: 72 years, 84% white, mean Charlson comorbidity index score: 1.1) received 1st line (mean duration: 289 days); 96 (38%) patients received 2nd line (mean duration: 267 days); and 34 (13%) received 3rd line therapy (mean duration: 253 days). Treatment pattern for each line of therapy were as follows, 1st line: ibrutinib-based (30%), chemotherapy- based (25%), rituximab monotherapy (25%), proteasome inhibitor-based (14%), and other (5%); 2nd line: chemotherapy-based (27%), ibrutinib-based (24%), rituximab monotherapy (23%), proteasome inhibitor- based (15%), and other (9%); 3rd line: ibrutinib- based (41%), rituximab monotherapy (32%), chemotherapy-based (18%), proteasome inhibitorbased (6%), and other (3%). The overall hospitalization rate was 29% with an average LOS of 12 days. Approximately 21% (LOS: 10.9 days), 18% (LOS: 6.9 days), and 24% (LOS: 7.3 days) of patients had a hospitalization, respectively, during 1st, 2nd, and 3rd line therapy. Average total PPPM costs overall were $13,007, and $13,154, $12,550, and $25,813 during 1st, 2nd, and 3rd line therapy, respectively.

BACKGROUND: Waldenström macroglobulinemia (WM) is a rare, incurable non-Hodgkin Lymphoma. There is limited real-world evidence on WM treatment among US Veterans.

OBJECTIVE: This retrospective observational study aims to evaluate the real-world treatment patterns and associated outcomes among patients with WM in the Veteran Health Administration (VHA) population.

METHODS: Adults who had ≥2 visits with WM diagnosis codes and ≥1 WM treatment were identified in VHA database (2014-2018). Index date was defined as the first date of WM treatment. Patients included were newly diagnosed, initiating treatment, and enrolled continuously for 6 months prior to and ≥60 days following index date. Treatment regimens were categorized as: rituximab monotherapy, ibrutinib-based, chemotherapybased, proteasome inhibitor-based and other regimens. Healthcare resource utilization examined included hospitalization and length-of-stay (LOS). Total costs were calculated as sum of inpatient, outpatient and pharmacy costs per-patient-per-month (PPPM).

RESULTS: Prevalence and incidence of WM among Veterans ranged from 11.4-12.8 cases, and 0.4-1.6 cases per 100,000 persons, respectively. A total of 255 patients (median age: 72 years, 84% white, mean Charlson comorbidity index score: 1.1) received 1st line (mean duration: 289 days); 96 (38%) patients received 2nd line (mean duration: 267 days); and 34 (13%) received 3rd line therapy (mean duration: 253 days). Treatment pattern for each line of therapy were as follows, 1st line: ibrutinib-based (30%), chemotherapy- based (25%), rituximab monotherapy (25%), proteasome inhibitor-based (14%), and other (5%); 2nd line: chemotherapy-based (27%), ibrutinib-based (24%), rituximab monotherapy (23%), proteasome inhibitor- based (15%), and other (9%); 3rd line: ibrutinib- based (41%), rituximab monotherapy (32%), chemotherapy-based (18%), proteasome inhibitorbased (6%), and other (3%). The overall hospitalization rate was 29% with an average LOS of 12 days. Approximately 21% (LOS: 10.9 days), 18% (LOS: 6.9 days), and 24% (LOS: 7.3 days) of patients had a hospitalization, respectively, during 1st, 2nd, and 3rd line therapy. Average total PPPM costs overall were $13,007, and $13,154, $12,550, and $25,813 during 1st, 2nd, and 3rd line therapy, respectively.

BACKGROUND: Waldenström macroglobulinemia (WM) is a rare, incurable non-Hodgkin Lymphoma. There is limited real-world evidence on WM treatment among US Veterans.

OBJECTIVE: This retrospective observational study aims to evaluate the real-world treatment patterns and associated outcomes among patients with WM in the Veteran Health Administration (VHA) population.

METHODS: Adults who had ≥2 visits with WM diagnosis codes and ≥1 WM treatment were identified in VHA database (2014-2018). Index date was defined as the first date of WM treatment. Patients included were newly diagnosed, initiating treatment, and enrolled continuously for 6 months prior to and ≥60 days following index date. Treatment regimens were categorized as: rituximab monotherapy, ibrutinib-based, chemotherapybased, proteasome inhibitor-based and other regimens. Healthcare resource utilization examined included hospitalization and length-of-stay (LOS). Total costs were calculated as sum of inpatient, outpatient and pharmacy costs per-patient-per-month (PPPM).

RESULTS: Prevalence and incidence of WM among Veterans ranged from 11.4-12.8 cases, and 0.4-1.6 cases per 100,000 persons, respectively. A total of 255 patients (median age: 72 years, 84% white, mean Charlson comorbidity index score: 1.1) received 1st line (mean duration: 289 days); 96 (38%) patients received 2nd line (mean duration: 267 days); and 34 (13%) received 3rd line therapy (mean duration: 253 days). Treatment pattern for each line of therapy were as follows, 1st line: ibrutinib-based (30%), chemotherapy- based (25%), rituximab monotherapy (25%), proteasome inhibitor-based (14%), and other (5%); 2nd line: chemotherapy-based (27%), ibrutinib-based (24%), rituximab monotherapy (23%), proteasome inhibitor- based (15%), and other (9%); 3rd line: ibrutinib- based (41%), rituximab monotherapy (32%), chemotherapy-based (18%), proteasome inhibitorbased (6%), and other (3%). The overall hospitalization rate was 29% with an average LOS of 12 days. Approximately 21% (LOS: 10.9 days), 18% (LOS: 6.9 days), and 24% (LOS: 7.3 days) of patients had a hospitalization, respectively, during 1st, 2nd, and 3rd line therapy. Average total PPPM costs overall were $13,007, and $13,154, $12,550, and $25,813 during 1st, 2nd, and 3rd line therapy, respectively.

BACKGROUND: Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma. There is limited data on MCL burden to US veterans. OBJECTIVE: This retrospective cohort analysis aims to examine the clinical burden, costs and healthcare resource utilization of MCL to veterans.

METHODS: Adults who were newly diagnosed with MCL and initiated treatment were identified in the Veteran Health Administration (VHA) dataset (2014-2018). Treatment regimens are mutually exclusive and categorized as: bendamustine-based (alone or in combination); BTK-based (Bruton’s tyrosine kinase inhibitors: ibrutinib or acalabrutinib, alone or in combination); RCHOP-based; rituximab-monotherapy; and other regimen. Treatment discontinuation is defined as no MCL treatment for 60 days from the last day of supply. Treatment regimens, costs and hospitalizations are examined by 1st, 2nd, and 3rd lines of therapy.

RESULTS: Prevalence and incidence of MCL among the VHA population ranged from 8-11 cases, and 0.6-2.6 cases per 100,000 persons, respectively. A total of 390 patients (mean age: 70 years, 85% white) received 1st line (mean duration: 243 days), 146 (37%) patients received 2nd line (mean duration: 259 days), and 47 (12%) received 3rd line (mean duration: 154 days) therapy. Bendamustine-based regimen was the most common 1st line MCL treatment (43%), with lower utilization later (2nd line: 18%; 3rd line: 2%). BTK-based regimen was the second most common 1st line MCL treatment (23%), and the most common MCL treatment in later settings (2nd line: 34%, 3rd line 28%). RCHOP-based regimens were seldomly used in any setting (<5%). The overall treatment discontinuation rate was 82%. Approximately 38% of MCL patients had a hospitalization, with mean length-of-stay (LOS) of 5.6 days. The hospitalization rate was 29% (mean LOS: 3.5), 36% (mean LOS: 4.4), and 26% (mean LOS: 3.1) during 1st, 2nd, and 3rd line, respectively. Per-patient-per-month costs were $19,338 overall, and $19,239, $20,064, and $27,663 respectively, during 1st, 2nd, and 3rd line of therapy.

CONCLUSION: This study showed that bendamustine- based and BTK-based regimens were the common frontline treatments among newly diagnosed MCL patients in the VHA population. Future studies are warranted to understand factors associated with treatment selection, discontinuation and clinical benefits among these MCL Veteran patients.

BACKGROUND: Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma. There is limited data on MCL burden to US veterans. OBJECTIVE: This retrospective cohort analysis aims to examine the clinical burden, costs and healthcare resource utilization of MCL to veterans.

METHODS: Adults who were newly diagnosed with MCL and initiated treatment were identified in the Veteran Health Administration (VHA) dataset (2014-2018). Treatment regimens are mutually exclusive and categorized as: bendamustine-based (alone or in combination); BTK-based (Bruton’s tyrosine kinase inhibitors: ibrutinib or acalabrutinib, alone or in combination); RCHOP-based; rituximab-monotherapy; and other regimen. Treatment discontinuation is defined as no MCL treatment for 60 days from the last day of supply. Treatment regimens, costs and hospitalizations are examined by 1st, 2nd, and 3rd lines of therapy.

RESULTS: Prevalence and incidence of MCL among the VHA population ranged from 8-11 cases, and 0.6-2.6 cases per 100,000 persons, respectively. A total of 390 patients (mean age: 70 years, 85% white) received 1st line (mean duration: 243 days), 146 (37%) patients received 2nd line (mean duration: 259 days), and 47 (12%) received 3rd line (mean duration: 154 days) therapy. Bendamustine-based regimen was the most common 1st line MCL treatment (43%), with lower utilization later (2nd line: 18%; 3rd line: 2%). BTK-based regimen was the second most common 1st line MCL treatment (23%), and the most common MCL treatment in later settings (2nd line: 34%, 3rd line 28%). RCHOP-based regimens were seldomly used in any setting (<5%). The overall treatment discontinuation rate was 82%. Approximately 38% of MCL patients had a hospitalization, with mean length-of-stay (LOS) of 5.6 days. The hospitalization rate was 29% (mean LOS: 3.5), 36% (mean LOS: 4.4), and 26% (mean LOS: 3.1) during 1st, 2nd, and 3rd line, respectively. Per-patient-per-month costs were $19,338 overall, and $19,239, $20,064, and $27,663 respectively, during 1st, 2nd, and 3rd line of therapy.

CONCLUSION: This study showed that bendamustine- based and BTK-based regimens were the common frontline treatments among newly diagnosed MCL patients in the VHA population. Future studies are warranted to understand factors associated with treatment selection, discontinuation and clinical benefits among these MCL Veteran patients.

BACKGROUND: Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma. There is limited data on MCL burden to US veterans. OBJECTIVE: This retrospective cohort analysis aims to examine the clinical burden, costs and healthcare resource utilization of MCL to veterans.

METHODS: Adults who were newly diagnosed with MCL and initiated treatment were identified in the Veteran Health Administration (VHA) dataset (2014-2018). Treatment regimens are mutually exclusive and categorized as: bendamustine-based (alone or in combination); BTK-based (Bruton’s tyrosine kinase inhibitors: ibrutinib or acalabrutinib, alone or in combination); RCHOP-based; rituximab-monotherapy; and other regimen. Treatment discontinuation is defined as no MCL treatment for 60 days from the last day of supply. Treatment regimens, costs and hospitalizations are examined by 1st, 2nd, and 3rd lines of therapy.

RESULTS: Prevalence and incidence of MCL among the VHA population ranged from 8-11 cases, and 0.6-2.6 cases per 100,000 persons, respectively. A total of 390 patients (mean age: 70 years, 85% white) received 1st line (mean duration: 243 days), 146 (37%) patients received 2nd line (mean duration: 259 days), and 47 (12%) received 3rd line (mean duration: 154 days) therapy. Bendamustine-based regimen was the most common 1st line MCL treatment (43%), with lower utilization later (2nd line: 18%; 3rd line: 2%). BTK-based regimen was the second most common 1st line MCL treatment (23%), and the most common MCL treatment in later settings (2nd line: 34%, 3rd line 28%). RCHOP-based regimens were seldomly used in any setting (<5%). The overall treatment discontinuation rate was 82%. Approximately 38% of MCL patients had a hospitalization, with mean length-of-stay (LOS) of 5.6 days. The hospitalization rate was 29% (mean LOS: 3.5), 36% (mean LOS: 4.4), and 26% (mean LOS: 3.1) during 1st, 2nd, and 3rd line, respectively. Per-patient-per-month costs were $19,338 overall, and $19,239, $20,064, and $27,663 respectively, during 1st, 2nd, and 3rd line of therapy.

CONCLUSION: This study showed that bendamustine- based and BTK-based regimens were the common frontline treatments among newly diagnosed MCL patients in the VHA population. Future studies are warranted to understand factors associated with treatment selection, discontinuation and clinical benefits among these MCL Veteran patients.